Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 January 2008, Vol. 111, No. 1, pp. 320-327.
Prepublished online as a Blood First Edition Paper on September 21, 2007; DOI 10.1182/blood-2007-05-092288.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2007-05-092288v1
111/1/320    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wies, E.
Right arrow Articles by Neipel, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wies, E.
Right arrow Articles by Neipel, F.
Related Collections
Right arrow Immunobiology
Right arrow Neoplasia
Right arrow Apoptosis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA

The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells

Effi Wies1, Yasuko Mori2, Alexander Hahn1, Elisabeth Kremmer3, Michael Stürzl4, Bernhard Fleckenstein1, and Frank Neipel1

1 Institut für Klinische und Molekulare Virologie, Universität Erlangen-Nürnberg, Erlangen, Germany; 2 Laboratory of Virology and Vaccinology, Division of Biomedical Research, National Institute of Biomedical Innovation, Osaka, Japan; 3 Forschungszentrum für Umwelt und Gesundheit (GSF)–Institut für Molekulare Immunologie, München, Germany; and 4 Abteilung für Molekulare und Experimentelle Chirurgie, Chirurgische Klinik, Universität Erlangen-Nürnberg, Erlangen, Germany

Human herpesvirus-8 (HHV-8), also known as Kaposi sarcoma–associated herpesvirus (KSHV), is etiologically linked to primary effusion lymphoma (PEL). At least 10 KSHV-encoded proteins with potential roles in KSHV-associated neoplasia have been identified. However, with few exceptions, these putative oncogenes were analyzed in heterologous systems only using overexpression of single genes. Thus, the pathogenetic relevance of most of these putative oncogenes remains essentially unclear. We used RNA interference (RNAi) to knock down the expression of several KSHV genes in cultured PEL cells carrying the KSHV genome. The viral interferon-regulatory factor-3 (vIRF-3) was found to be required for proliferation and survival of cultured PEL cells. Knock-down of vIRF-3 expression by various RNAi approaches unequivocally resulted in reduced proliferation and increased activity of caspase-3 and/or caspase-7. Thus, vIRF-3 can be seen as a bona fide oncogene of KSHV-associated lymphoma. Surprisingly, although the related Epstein-Barr virus (EBV) is usually sufficient to immortalize human B lymphocytes, silencing of vIRF-3 reduced the viability of both EBV– and EBV+ PEL cells. This suggests that KSHV is the driving force in the pathogenesis of PEL.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
E. Wies, A. S. Hahn, K. Schmidt, C. Viebahn, N. Rohland, A. Lux, T. Schellhorn, A. Holzer, J. U. Jung, and F. Neipel
The Kaposi's Sarcoma-associated Herpesvirus-encoded vIRF-3 Inhibits Cellular IRF-5
J. Biol. Chem., March 27, 2009; 284(13): 8525 - 8538.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
A. Konrad, E. Wies, M. Thurau, G. Marquardt, E. Naschberger, S. Hentschel, R. Jochmann, T. F. Schulz, H. Erfle, B. Brors, et al.
A Systems Biology Approach To Identify the Combination Effects of Human Herpesvirus 8 Genes on NF-{kappa}B Activation
J. Virol., March 15, 2009; 83(6): 2563 - 2574.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Carbone, E. Cesarman, M. Spina, A. Gloghini, and T. F. Schulz
HIV-associated lymphomas and gamma-herpesviruses
Blood, February 5, 2009; 113(6): 1213 - 1224.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
R. Subramanian, O. D'Auvergne, H. Kong, and K. G. Kousoulas
The Cytoplasmic Terminus of Kaposi's Sarcoma-Associated Herpesvirus Glycoprotein B Is Not Essential for Virion Egress and Infectivity
J. Virol., July 15, 2008; 82(14): 7144 - 7154.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020